DD150609A5 - Verfahren zur herstellung von pyrimidin-verbindungen - Google Patents

Verfahren zur herstellung von pyrimidin-verbindungen Download PDF

Info

Publication number
DD150609A5
DD150609A5 DD80221082A DD22108280A DD150609A5 DD 150609 A5 DD150609 A5 DD 150609A5 DD 80221082 A DD80221082 A DD 80221082A DD 22108280 A DD22108280 A DD 22108280A DD 150609 A5 DD150609 A5 DD 150609A5
Authority
DD
German Democratic Republic
Prior art keywords
amino
pyrimidinyl
methyl
group
formula
Prior art date
Application number
DD80221082A
Other languages
German (de)
English (en)
Inventor
Adrian Marxer
Kurt Eichenberger
Original Assignee
Ciba Geigy Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ciba Geigy Ag filed Critical Ciba Geigy Ag
Publication of DD150609A5 publication Critical patent/DD150609A5/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
    • C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
    • C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
    • C07D239/32—One oxygen, sulfur or nitrogen atom
    • C07D239/42—One nitrogen atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
    • C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
    • C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
    • C07D239/46—Two or more oxygen, sulphur or nitrogen atoms
    • C07D239/47—One nitrogen atom and one oxygen or sulfur atom, e.g. cytosine
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
    • C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
    • C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
    • C07D239/46—Two or more oxygen, sulphur or nitrogen atoms
    • C07D239/48—Two nitrogen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
    • C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
    • C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
    • C07D239/46—Two or more oxygen, sulphur or nitrogen atoms
    • C07D239/52—Two oxygen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
    • C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
    • C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
    • C07D239/46—Two or more oxygen, sulphur or nitrogen atoms
    • C07D239/52—Two oxygen atoms
    • C07D239/54—Two oxygen atoms as doubly bound oxygen atoms or as unsubstituted hydroxy radicals
    • C07D239/545—Two oxygen atoms as doubly bound oxygen atoms or as unsubstituted hydroxy radicals with other hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Cardiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Hospice & Palliative Care (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
DD80221082A 1979-05-18 1980-05-13 Verfahren zur herstellung von pyrimidin-verbindungen DD150609A5 (de)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
CH466979 1979-05-18

Publications (1)

Publication Number Publication Date
DD150609A5 true DD150609A5 (de) 1981-09-09

Family

ID=4280399

Family Applications (1)

Application Number Title Priority Date Filing Date
DD80221082A DD150609A5 (de) 1979-05-18 1980-05-13 Verfahren zur herstellung von pyrimidin-verbindungen

Country Status (21)

Country Link
EP (1) EP0019811A1 (fr)
JP (1) JPS55154971A (fr)
KR (1) KR830002757A (fr)
AR (1) AR228256A1 (fr)
AU (1) AU5848480A (fr)
DD (1) DD150609A5 (fr)
DK (1) DK214480A (fr)
ES (1) ES491514A0 (fr)
FI (1) FI801600A7 (fr)
GB (1) GB2052487B (fr)
GR (1) GR68453B (fr)
IE (1) IE49803B1 (fr)
IL (1) IL60086A (fr)
MA (1) MA18829A1 (fr)
NO (1) NO801469L (fr)
NZ (1) NZ193730A (fr)
OA (1) OA06533A (fr)
PL (1) PL224313A1 (fr)
PT (1) PT71251A (fr)
ZA (1) ZA802909B (fr)
ZW (1) ZW11880A1 (fr)

Families Citing this family (30)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4507146A (en) * 1982-12-28 1985-03-26 Ciba-Geigy Corporation 2,4-Diamino-6-halo-5-trifluoromethylpyrimidines having herbicidal activity
DE3829469A1 (de) * 1988-08-31 1990-03-01 Bayer Ag Verfahren zur herstellung von substituierten n-azinyl-n'-sulfonyl-isothioharnstoffen und n-azinyl-iminodithiokohlensaeure-s,s-diester als zwischenprodukte zu ihrer herstellung
WO1999011269A1 (fr) * 1997-09-03 1999-03-11 Eli Lilly And Company Derives de pyrimidine
WO2002022605A1 (fr) 2000-09-15 2002-03-21 Vertex Pharmaceuticals Incorporated Composes de pyrazole utiles comme inhibiteurs de proteine kinase
US6660731B2 (en) 2000-09-15 2003-12-09 Vertex Pharmaceuticals Incorporated Pyrazole compounds useful as protein kinase inhibitors
US7473691B2 (en) 2000-09-15 2009-01-06 Vertex Pharmaceuticals Incorporated Pyrazole compounds useful as protein kinase inhibitors
US6989385B2 (en) 2000-12-21 2006-01-24 Vertex Pharmaceuticals Incorporated Pyrazole compounds useful as protein kinase inhibitors
CA2671776C (fr) * 2001-01-31 2012-12-18 H. Lundbeck A/S Antagonistes du recepteur gal3 servant a traiter une depression
MXPA04008901A (es) 2002-03-13 2004-11-26 Euro Celtique Sa Pirimidinas arilo sustituidas y el uso de las mismas.
US20040009981A1 (en) 2002-03-15 2004-01-15 David Bebbington Compositions useful as inhibitors of protein kinases
US7731985B2 (en) * 2002-03-15 2010-06-08 Ciba Specialty Chemicals Corporation 4-aminopyrimidines and their use for the antimicrobial treatment of surfaces
MY141867A (en) 2002-06-20 2010-07-16 Vertex Pharma Substituted pyrimidines useful as protein kinase inhibitors
CN1319968C (zh) 2002-08-02 2007-06-06 沃泰克斯药物股份有限公司 用作gsk－3的抑制剂的吡唑组合物
US7601718B2 (en) 2003-02-06 2009-10-13 Vertex Pharmaceuticals Incorporated Compositions useful as inhibitors of protein kinases
ATE542814T1 (de) 2005-08-18 2012-02-15 Vertex Pharma Pyrazinkinaseinhibitoren
MX2008005814A (es) 2005-11-03 2008-10-15 Vertex Pharma Aminopirimidinas utiles como inhibidores de cinasa.
CA2668429A1 (fr) 2006-11-02 2008-05-15 Vertex Pharmaceuticals Incorporated Aminopyridines et aminopyrimidines utiles en tant qu'inhibiteurs de proteines kinases
ES2347721T3 (es) 2006-12-19 2010-11-03 Vertex Pharmaceuticals, Inc. Aminopirimidinas utiles como inhibidores de proteina quinasas.
EP2137183B1 (fr) 2007-03-09 2011-09-28 Vertex Pharmaceuticals Incorporated Aminopyrimidines utiles en tant qu'inhibiteurs des protéines kinases
EP2134709A1 (fr) 2007-03-09 2009-12-23 Vertex Pharmaceuticals, Inc. Utilisation des aminopyridines comme inhibiteurs de protéines kinases
AU2008226457B2 (en) 2007-03-09 2014-03-20 Vertex Pharmaceuticals Incorporated Aminopyrimidines useful as inhibitors of protein kinases
NZ580343A (en) 2007-04-13 2012-03-30 Vertex Pharma Aminopyrimidines useful as kinase inhibitors
CA2694381A1 (fr) 2007-05-02 2008-11-13 Vertex Pharmaceuticals Incorporated Aminopyrimidines servant d'inhibiteurs de kinases
JP5389785B2 (ja) 2007-05-02 2014-01-15 バーテックス ファーマシューティカルズ インコーポレイテッド キナーゼ阻害剤として有用なチアゾールおよびピラゾール
NZ582879A (en) 2007-07-31 2012-03-30 Vertex Pharma Process for preparing 5-fluoro-1h-pyrazolo [3, 4-b] pyridin-3-amine and derivatives thereof
MX2011002312A (es) 2008-09-03 2011-04-26 Vertex Pharma Co-cristales y formulaciones farmaceuticas que comprenden los mismos.
RS53347B (sr) * 2008-12-09 2014-10-31 Gilead Sciences, Inc. Modulatori toll-sličnih receptora
KR102328682B1 (ko) * 2018-08-27 2021-11-18 주식회사 대웅제약 신규한 헤테로사이클릭아민 유도체 및 이를 포함하는 약학 조성물
WO2022101435A1 (fr) * 2020-11-12 2022-05-19 3Z Ehf Nouveaux traitements du trouble du déficit de l'attention/hyperactivité
CN121494792A (zh) * 2026-01-14 2026-02-10 山东国邦药业有限公司 一种5-甲氧基-4,6-二羟基嘧啶的制备方法

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BE754832A (fr) * 1969-08-14 1971-02-15 Beecham Group Ltd Iminazolines

Also Published As

Publication number Publication date
FI801600A7 (fi) 1981-01-01
PL224313A1 (fr) 1981-02-13
OA06533A (fr) 1981-07-31
ZA802909B (en) 1981-05-27
ZW11880A1 (en) 1980-12-17
MA18829A1 (fr) 1980-12-31
EP0019811A1 (fr) 1980-12-10
GB2052487A (en) 1981-01-28
DK214480A (da) 1980-11-19
AR228256A1 (es) 1983-02-15
KR830002757A (ko) 1983-05-30
IL60086A0 (en) 1980-07-31
NZ193730A (en) 1982-12-21
IL60086A (en) 1984-03-30
ES8104279A1 (es) 1981-04-16
IE49803B1 (en) 1985-12-25
NO801469L (no) 1980-11-19
JPS55154971A (en) 1980-12-02
GB2052487B (en) 1983-05-11
IE801023L (en) 1980-11-18
ES491514A0 (es) 1981-04-16
PT71251A (en) 1980-06-01
GR68453B (fr) 1981-12-30
AU5848480A (en) 1980-11-20

Similar Documents

Publication Publication Date Title
DD150609A5 (de) Verfahren zur herstellung von pyrimidin-verbindungen
DE69530989T2 (de) Neue pyrimidinderivate und verfahren zu ihrer herstellung
DE69636671T2 (de) Pyrido[2,3-]-pyrimidine und deren Verwendung beim Inhibieren von Zellproliferation und Protein-Tyrosin-Kinase-Enzymaktivität
DE2341925A1 (de) Neue pyrimidinderivate und verfahren zu ihrer herstellung
CH642965A5 (de) Substituierte 5-(2-imidazolin-2-yl)-aminopyrimidine und verfahren zu deren herstellung.
DE2309160A1 (de) 2-imidazolin-2-yl-amino-substituierte, benzokondensierte, heterocyclische verbindungen und arzneipraeparate
DD216934A5 (de) Verfahren zur herstellung neuer derivate von xanthinen
DE2720085C2 (fr)
DE2849537A1 (de) Substituierte 5-(2-imidazolin-2-yl)- aminopyrimidine und verfahren zu deren herstellung
DE60004671T2 (de) Neue piperazinylalkylthiopyrimidine derivate, diese enthaltende pharmazeutische zusammenstellungen und verfahren zu deren herstellung
DE2062024A1 (de) Tetrahydro-imidazo- und Tetrahydropyrimido- eckige Klammer auf 2,1-b eckige Klammer zu -chinazoline, ihre Salze mit Säuren, Verfahren zu ihrer Herstellung und Arzneipräparate
EP0122580A1 (fr) Derivés de la pyrimidine, leur préparation et compositions pharmaceutiques
EP0047328B1 (fr) Dérivés de 1H- et 2H-indazole et médicament les contenant
EP0288431B1 (fr) 3H-1,2,3-triazolo[4,5-d]pyrimidines
DE2133998A1 (de) 2,3-dihydro-oxo-imidazo eckige klammer auf 1,2-a eckige klammer zu -pyrimidine, deren saeureadditionssalze und verfahren zu deren herstellung
DE2918778A1 (de) 6-substituierte 11-alkylen-morphantridine
EP0093252B1 (fr) Dérivés de thiométhylpyridine, procédé pour leur préparation et médicaments les contenant
EP0124893A2 (fr) Dérivés de pyrimidone
EP0124630B1 (fr) Dérivés de pyrimidinothioalkyle pyridine, procédé pour leur préparation et médicaments contenant ces composés
DE3807084A1 (de) Neue benzimidazo(1,2-c)chinazoline, ihre herstellung und verwendung
DE2139083A1 (de) Substituierte pyrimidine, verfahren zu deren herstellung und sie enthaltende arzneimittel
DD220780A5 (de) Verfahren zur herstellung von 5-subst.-(1,2,4) triazolo (1,5-c) pryimidin-2-aminen
CH591457A5 (fr)
EP0056027A1 (fr) 2-(1-piperazinyl)-4-pyrinidinamines
DE833651C (de) Verfahren zur Herstellung von neuen Pyrimidinabkoemmlingen